Literature DB >> 15897565

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.

Andrew Berchuck1, Edwin S Iversen, Johnathan M Lancaster, Jennifer Pittman, Jingqin Luo, Paula Lee, Susan Murphy, Holly K Dressman, Phillip G Febbo, Mike West, Joseph R Nevins, Jeffrey R Marks.   

Abstract

PURPOSE: A better understanding of the underlying biology of invasive serous ovarian cancer is critical for the development of early detection strategies and new therapeutics. The objective of this study was to define gene expression patterns associated with favorable survival. EXPERIMENTAL
DESIGN: RNA from 65 serous ovarian cancers was analyzed using Affymetrix U133A microarrays. This included 54 stage III/IV cases (30 short-term survivors who lived <3 years and 24 long-term survivors who lived >7 years) and 11 stage I/II cases. Genes were screened on the basis of their level of and variability in expression, leaving 7,821 for use in developing a predictive model for survival. A composite predictive model was developed that combines Bayesian classification tree and multivariate discriminant models. Leave-one-out cross-validation was used to select and evaluate models.
RESULTS: Patterns of genes were identified that distinguish short-term and long-term ovarian cancer survivors. The expression model developed for advanced stage disease classified all 11 early-stage ovarian cancers as long-term survivors. The MAL gene, which has been shown to confer resistance to cancer therapy, was most highly overexpressed in short-term survivors (3-fold compared with long-term survivors, and 29-fold compared with early-stage cases). These results suggest that gene expression patterns underlie differences in outcome, and an examination of the genes that provide this discrimination reveals that many are implicated in processes that define the malignant phenotype.
CONCLUSIONS: Differences in survival of advanced ovarian cancers are reflected by distinct patterns of gene expression. This biological distinction is further emphasized by the finding that early-stage cancers share expression patterns with the advanced stage long-term survivors, suggesting a shared favorable biology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897565     DOI: 10.1158/1078-0432.CCR-04-2398

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  103 in total

1.  Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time.

Authors:  Elizabeth M Swisher; Toshiyasu Taniguchi; Beth Y Karlan
Journal:  J Natl Cancer Inst       Date:  2012-04-13       Impact factor: 13.506

2.  Bayesian ensemble methods for survival prediction in gene expression data.

Authors:  Vinicius Bonato; Veerabhadran Baladandayuthapani; Bradley M Broom; Erik P Sulman; Kenneth D Aldape; Kim-Anh Do
Journal:  Bioinformatics       Date:  2010-12-08       Impact factor: 6.937

3.  Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.

Authors:  Celeste Leigh Pearce; Jennifer A Doherty; David J Van Den Berg; Kirsten Moysich; Chris Hsu; Kara L Cushing-Haugen; David V Conti; Susan J Ramus; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Paul D P Pharoah; Honglin Song; Susanne K Kjaer; Estrid Hogdall; Claus Hogdall; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Jacek Gronwald; Krzysztof Medrek; Anna Jakubowska; Jan Lubinski; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M Webb; Andrew Berchuck; Joellen M Schildkraut; Edwin S Iversen; Patricia G Moorman; Christopher K Edlund; Daniel O Stram; Malcolm C Pike; Roberta B Ness; Mary Anne Rossing; Anna H Wu
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

Review 4.  Contemporary progress in ovarian cancer screening.

Authors:  Christine S Walsh; B Y Karlan
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

5.  Bayesian Weibull tree models for survival analysis of clinico-genomic data.

Authors:  Jennifer Clarke; Mike West
Journal:  Stat Methodol       Date:  2008

Review 6.  Novel biomarkers in type 1 diabetes.

Authors:  Yulan Jin; Jin-Xiong She
Journal:  Rev Diabet Stud       Date:  2012-12-28

7.  Structured Matrix Completion with Applications to Genomic Data Integration.

Authors:  Tianxi Cai; T Tony Cai; Anru Zhang
Journal:  J Am Stat Assoc       Date:  2016-08-18       Impact factor: 5.033

Review 8.  Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.

Authors:  Analisa DiFeo; Goutham Narla; John A Martignetti
Journal:  Mt Sinai J Med       Date:  2009-12

9.  Biomarkers for type 1 diabetes.

Authors:  Sharad Purohit; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2008-02-29

10.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Authors:  Samuel C Mok; Tomas Bonome; Vinod Vathipadiekal; Aaron Bell; Michael E Johnson; Kwong-kwok Wong; Dong-Choon Park; Ke Hao; Daniel K P Yip; Howard Donninger; Laurent Ozbun; Goli Samimi; John Brady; Mike Randonovich; Cindy A Pise-Masison; J Carl Barrett; Wing H Wong; William R Welch; Ross S Berkowitz; Michael J Birrer
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.